In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Enlicitide | Synthetic analog Semaglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 33 | 4,624 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 8 (8 in people) | 1,224 (1,221 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 34 · 8 active | 663 · 284 active124 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Lipfendra says: “Adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Enlicitide | Semaglutide |
|---|---|---|
| Adverse eventsWhole body | 88 | 7757723 |
| LipidsMetabolic and weight |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Ozempic says: “Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; reduce the risk of sustained eGFR decline…”
2424
1181171 |
| Receptor activity and mechanismPharmacology | 11 | 91611 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Semaglutide differs from Glucagon-like peptide 1 (7-37) at 2 positions and carries 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Enlicitide | Semaglutide |
|---|---|---|
| LipidsMetabolic and weightCompared as: difference from placebo, in % | −53% Between-group difference in mean percentage change in Non-HDL-C Dose studied: 20 mg once daily52 weeksn = 3032026 | −8.02% Non-HDL-C change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 39.5 to 43.4% Adverse events · MK-0616 arms Placebo: 44% Dose studied: 6, 12, 18 or 30 mg once daily8 weeksn not reported2023 | 86.2% Adverse events · semaglutide 0.5 mg |
−53%
Between-group difference in mean percentage change in Non-HDL-C
Dose studied: 20 mg once daily52 weeksn = 3032026
−8.02%
Non-HDL-C change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
39.5 to 43.4%
Adverse events · MK-0616 arms
Placebo: 44%
Dose studied: 6, 12, 18 or 30 mg once daily8 weeksn not reported2023
86.2%
Adverse events · semaglutide 0.5 mg
Dose studied: 0.5 mg56 weeksn = 6012018
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 34 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Merck Sharp & Dohme LLC2,912 participants10 Aug 2023 to 28 Jul 2025
Hypercholesterolemia · Familial Hypercholesterolemia
Merck Sharp & Dohme LLC303 participants8 Aug 2023 to 7 Apr 2025
Hypercholesterolemia · Familial Hypercholesterolemia
Merck Sharp & Dohme LLC301 participants8 Jul 2024 to 28 Mar 2025
Hypercholesterolemia
Top 3 of 663 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S17,604 participants24 Oct 2018 to 29 Jun 2023
Overweight · Obesity
Novo Nordisk A/S9,651 participants17 Jun 2019 to 23 Aug 2024
Diabetes Mellitus, Type 2
Novo Nordisk A/S3,533 participants17 Jun 2019 to 9 Jan 2024
Diabetes Mellitus, Type 2
124 more mention it but do not test it. They only measure it or name it in their text.